NCT02896413View on ClinicalTrials.gov

The Effects of Perioperative Dexmedetomidine Administration on Immune Suppression and Outcomes in Patients With Uterine Cancer Undergoing Radical Resection

NACompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

June 2, 2016

Primary Completion Date

October 24, 2018

Study Completion Date

October 24, 2018

Conditions
Uterine Cancer
Interventions
DRUG

Dexmedetomidine group

dexmedetomidine infusion (0.4 mcg/kg/h) from immediately after anesthetic induction to 24 h after surgery

DRUG

Control group

0.9% saline infusion

Trial Locations (1)

03722

Department of Anesthesiology and Pain Medicine, Anesthesia and Pain Research Institue, Yonsei Universiy College of Medicine, Seoul

All Listed Sponsors
lead

Yonsei University

OTHER

NCT02896413 - The Effects of Perioperative Dexmedetomidine Administration on Immune Suppression and Outcomes in Patients With Uterine Cancer Undergoing Radical Resection | Biotech Hunter | Biotech Hunter